Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 3065-3072

  Fullmer, Amber ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Nilotinib; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CARBAMAZEPINE; CLARITHROMYCIN; CYTARABINE; DEXAMETHASONE; ESOMEPRAZOLE; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; NILOTINIB; PHENOBARBITAL; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; FATIGUE; FOOD DRUG INTERACTION; GENE MUTATION; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PROTEIN DOMAIN; PRURITUS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 78649292029     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.535655     Document Type: Review

References (39)

1. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
3. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:abstract 1126
4. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61
5. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia. Clin Cancer Res 2006;12:7374-9
6. Shah NP, Nicoll JM, Nager B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25
7. Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-92
8. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53-5
9. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987-90
10. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-53
11. Tasigna (nilotinib) [Package insert]. East Hanover, NJ: Novartis; 2010
12. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
13. Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor Bcr-Abl. Br J Cancer 2006;7:129-41
14. O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005;7:1117-19
15. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relative imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5
16. Von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108:1328-33
17. Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112-20
18. Griffin JD, Weisberg EL. Simultaneous administration of AMN107 and imatinib in the treatment of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia. Blood 2005;106:abstract 694
19. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51 (Pubitemid 43882350)
20. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
21. Le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9
22. Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009;114:abstract 1129
23. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-10
24. Hochhaus A, Giles F, Apperely J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24 month follow-up results of a phase 2 study. Haematologica 2009;94:abstract 0631
25. Giles FJ, Kantarjian H, le Coutre PD, et al. Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. J Clin Oncol 2010;28:abstract 6510
26. Giles F, Kantarjian HM, le Coutre P, et al. Nilotinib induces rapid and durable responses with 24-month minimum follow-up in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis (CML-BC). Haematologica 2010;95:abstract 1138
27. Nicolini FE, Kim DW, Ceglarek B, et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1, 422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CM) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood 2009;114:abstract 2201
28. Le Coutre PD, Turkina A, Kim DW, et al. Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood 2009;114:abstract 3286
29. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7
30. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-8
31. O'Dwyer M, Kent E, Parker M, et al. Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 Phase 2 study. Blood 2009;114:abstract 3294
32. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;262:2251-9
33. Guilhot F, Mahon FX, Guilhot J, et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML group (FI LMC). Blood 2008;112:abstract 183
34. Shah NP, Nicoll JM, Branford S, et al. Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: rational for combination tyrosine kinase inhibitor therapy. Blood 2005;106:abstract 1093
35. Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267-75
36. Tanaka C, Yin OQP, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87:197-203
37. Yin OPQ, Gallagher N, Li A, et al. Effect of grapefruit juice on the pharmacokinetics of nilotinib in health participants. J Clin Pharmacol 2010;50:188-94
38. Tanaka C. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in health participants. J Clin Pharmacol 2010. [Epub 11 August 2010] doi: 10.1177/0091270010367428
39. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010;50:960-7